CoreValve vs Sapien Outcome Predictor

Clinical calculation support · Verify results before clinical use

Patient profile and valve platform

Enter the clinical variables for a structured discussion. These inputs do not generate a validated individualized risk estimate.

ClinicalDecision aid
Use the value from the validated STS calculator; this page does not calculate STS-PROM.
Use the echocardiographic assessment documented for the patient.
Reset form

How to use this decision aid

This page records selected clinical characteristics and displays evidence-aware considerations. It is not a validated comparative risk score and should not be used to estimate mortality or a composite adverse-event probability.

Factors relevant to valve selection

  • Annular anatomy and haemodynamics: CT measurements, annular size, calcification distribution, and expected residual gradients can influence platform choice.
  • Conduction system: Baseline conduction disease, implantation depth, and platform-specific pacemaker risk should be considered.
  • Paravalvular regurgitation: Annular and LVOT calcification, sizing, sealing-skirt design, and deployment technique affect risk.
  • Lifetime management: Coronary access, future coronary intervention, and potential valve-in-valve procedures may matter.
  • Patient-level risk: STS-PROM and LVEF inform overall assessment but do not independently determine which transcatheter valve is best.

Evidence summary

Outcome / issueWhat comparative evidence supports
MortalityComparative studies and meta-analysis have not established a consistent mortality advantage for one platform across all patients.
Pacemaker implantationSome comparisons report higher permanent pacemaker rates with Evolut-family self-expanding valves than with SAPIEN balloon-expandable valves; individual risk varies.
Small annulusIn the SMART trial population with a small annulus, a supra-annular self-expanding platform had superior valve haemodynamic performance and non-inferior clinical outcomes at one year.
Overall choiceInterpret results in the context of anatomy, the specific device generation, procedural factors, patient preferences, and Heart Team judgement.

References

2025 ESC/EACTS Guidelines for the management of valvular heart disease.European Heart Journal (2025)
Wang B, et al. Comparison of outcomes of self-expanding versus balloon-expandable valves for transcatheter aortic valve replacement: a meta-analysis of randomized and propensity-matched studies.BMC Cardiovascular Disorders. 2023; DOI: 10.1186/s12872-023-03397-3
SMART trial: Self-expanding vs. balloon-expandable valve for TAVR in patients with small valve annulus.American College of Cardiology trial summary (2024)
OPERA-TAVI registry: One-year clinical outcomes of contemporary self-expanding or balloon-expandable devices.Open-access article (2023)
Clinical disclaimer: This educational decision aid does not provide an individualized risk prediction, does not replace a validated STS-PROM calculation, CT-based procedural planning, device instructions for use, or multidisciplinary Heart Team assessment. Evidence may differ by device generation, anatomy, access route, and patient population. Do not use this page as the sole basis for clinical decisions.